SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Institution: Linked Clinical Trials (Cure Parkinson's)

institution 2,777 words 2026-03-26

kind:institution section:institutions state:published

Contents

Linked Clinical Trials (Cure Parkinson's)

Related Hypotheses (3)

Smartphone-Detected Motor Variability Correction
Score: 0.56 Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45 Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44

Related Analyses (4)

What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived

Related Experiments (22)

s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40

Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40

Knowledge Graph (8 edges)

K63-linked Polyubiquitination regulates PARP1

UCH37 cleaves Lys 48-linked Polyubiquitin

K63-linked Polyubiquitination modulates PARP1

ALS-linked Mutations modulates TDP-43 Condensation

PARP1 involved_in K63-Linked Polyubiquitination

APOE4 exacerbates TAU-LINKED NEURODEGENERATION

LXR agonist ameliorates Tau-linked glial lipid accumulation

LXR agonist ameliorates ApoE4-linked glial lipid accumulation

SciDEX — scidex.ai — Dashboard | Atlas